{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:14:37Z","timestamp":1794060877477,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omtn.2025.102803","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:01:41Z","timestamp":1765526501000},"page":"102803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Spleen-targeted mRNA delivery via long-chain PEGylated lipids at low molar ratio enhances antitumor immunity against melanoma"],"prefix":"10.1016","volume":"37","author":[{"given":"Shiyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Yee","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7415-6997","authenticated-orcid":false,"given":"Feng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102803_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtn.2025.102803_bib2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102803_bib3","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102803_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102803_bib5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102803_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12951-024-02634-x","article-title":"Exosome for mRNA delivery: strategies and therapeutic applications","volume":"22","author":"Iqbal","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2025.102803_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102803_bib8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2025.102803_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtn.2025.102803_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s43586-023-00246-7","article-title":"Nanotechnology-based mRNA vaccines","volume":"3","author":"Chen","year":"2023","journal-title":"Nat. Rev. Methods Primers"},{"key":"10.1016\/j.omtn.2025.102803_bib11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omtn.2025.102803_bib12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102803_bib13","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.1021\/acs.nanolett.2c03741","article-title":"The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure","volume":"22","author":"Paunovska","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2025.102803_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41577-023-00857-x","article-title":"Splenic stromal niches in homeostasis and immunity","volume":"23","author":"Alexandre","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2025.102803_bib15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102803_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13346-016-0304-0","article-title":"Nanocarriers for spleen targeting: anatomo-physiological considerations, formulation strategies and therapeutic potential","volume":"6","author":"Jindal","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.omtn.2025.102803_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2019.09.009","article-title":"Spleen selective enhancement of transfection activities of plasmid DNA driven by octaarginine and an ionizable lipid and its implications for cancer immunization","volume":"313","author":"Kimura","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2025.102803_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2023.03.041","article-title":"Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses","volume":"357","author":"Pan","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omtn.2025.102803_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jconrel.2023.11.008","article-title":"Simultaneous dendritic cells targeting and effective endosomal escape enhance sialic acid-modified mRNA vaccine efficacy and reduce side effects","volume":"364","author":"Tang","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2025.102803_bib20","article-title":"Elucidation of lipid nanoparticle surface structure in mRNA vaccines","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102803_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.882363","article-title":"Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines","volume":"10","author":"Pad\u00edn-Gonz\u00e1lez","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102803_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2025.102803_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12951-024-02812-x","article-title":"Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA","volume":"22","author":"Kong","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2025.102803_bib24","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2025.102803_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol Ther-Nucl Acids"},{"key":"10.1016\/j.omtn.2025.102803_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6085","article-title":"Structure and function of the immune system in the spleen","volume":"4","author":"Lewis","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omtn.2025.102803_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The Spleen in Local and Systemic Regulation of Immunity","volume":"39","author":"Bronte","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2025.102803_bib28","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1039\/c3nr05559k","article-title":"Effect of polyethyleneglycol (PEG) chain length on the bio\u2013nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells","volume":"6","author":"Pozzi","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.omtn.2025.102803_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(97)00128-2","article-title":"Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo","volume":"32","author":"Cullis","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102803_bib30","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/acs.nanolett.8b00432","article-title":"A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation","volume":"18","author":"Paunovska","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2025.102803_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/vaccines13040339","article-title":"Exploring the Challenges of Lipid Nanoparticle Development: The In Vitro\u2013In Vivo Correlation Gap","volume":"13","author":"Lindsay","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.omtn.2025.102803_bib32","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2025.102803_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100923","article-title":"Nanovaccine\u2019s rapid induction of anti-tumor immunity significantly improves malignant cancer immunotherapy","volume":"35","author":"Zhang","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.omtn.2025.102803_bib34","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1016\/j.cell.2022.10.006","article-title":"Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment","volume":"185","author":"Baharom","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102803_bib35","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1021\/acs.jpcb.5b02891","article-title":"Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems","volume":"119","author":"Leung","year":"2015","journal-title":"J. Phys. Chem. B"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:13:05Z","timestamp":1780103585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162253125003579"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102803","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spleen-targeted mRNA delivery via long-chain PEGylated lipids at low molar ratio enhances antitumor immunity against melanoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102803"}}